Value of the new WHO pathological classification of pituitary tumors in diagnosis and treatment of clinically non-functioning pituitary adenomas
10.11855/j.issn.0577-7402.1810.2025.0304
- VernacularTitle:WHO垂体瘤新病理分类对临床无功能垂体瘤诊治的价值浅析
- Author:
Tian SUN
1
;
Xue-Dong ZHANG
;
Er-Han ZHENG
;
Hao SHEN
;
Tao ZHOU
;
Xiang-Hui MENG
;
Qing-Hua GUO
Author Information
1. 解放军总医院第一医学中心内分泌科,北京 100853;陕西省核工业二一五医院内分泌科,陕西 咸阳 712000
- Keywords:
non-functioning pituitary tumor;
pathological classification;
transcription factors;
diagnosis;
treatment
- From:
Medical Journal of Chinese People's Liberation Army
2025;50(4):387-392
- CountryChina
- Language:Chinese
-
Abstract:
Non-functioning pituitary adenomas(NFPAs)are relatively common.Apart from hyperprolactinemia caused by pituitary compression,they typically lack overt hormonal hypersecretion and usually present with clinical symptoms due to mass effects.Previously considered a uniform entity,NFPAs are actually a highly heterogeneous group of tumors,including aggressive subtypes like silent corticotroph adenomas(SCA)and null cell adenomas.The 2022 WHO new classification of pituitary tumors employs transcription factors[e.g.,pituitary-specific transcription factor 1(PIT-1),T-box transcription factor 19(TBX19,also known as TPIT),steroidogenic factor 1(SF-1)]for detailed categorization,allowing precise subclassification of NFPAs into multiple subtypes derived from distinct cell lineages,including silent gonadotroph adenomas,SCA,and plurihormonal PIT-1-positive adenomas.This helps identify highly invasive subtypes with high recurrence risk,guiding clinical diagnosis and treatment,prognostic assessment,and individualized management.The new classification also provides a theoretical basis for targeted therapies of NFPAs(e.g.,somatostatin analogs and temozolomide).This review comprehensively discusses the latest pathological classification of NFPAs and its clinical implications,aiming to enhance understanding of this disease and offer valuable insights for precise diagnosis,treatment,and prognostic assessment.
